Literature DB >> 19137768

Subantimicrobial-dose doxycycline in the treatment of moderate facial acne.

Parviz Toossi1, Mehdi Farshchian, Farhad Malekzad, Nahid Mohtasham, Arash Kimyai-Asadi.   

Abstract

BACKGROUND: Acne is a common inflammatory skin disorder. Oral antibiotics play a significant clinical role in treating acne.
OBJECTIVE: The purpose of this study was to compare the efficacy of doxycycline at antimicrobial and subantimicrobial doses for the treatment of acne.
METHODS: A prospective, randomized, double-blind, controlled trial was performed. One hundred patients with moderate facial acne were randomized into 2 treatment groups, one receiving a tablet containing 20 mg of doxycycline to be taken twice daily and the other receiving a tablet containing 100 mg of doxycycline and a matching placebo tablet to be taken twice daily.
RESULTS: Subantimicrobial-dose doxycycline administered twice daily for 3 months in patients with moderate inflammatory acne results in significant reduction in the number of total inflammatory lesions. There was an 84% reduction in number of papules and a 90% reduction in number of pustules with treatment.
CONCLUSION: Subantimicrobial-dose doxycycline is an effective treatment for patients with moderate acne vulgaris.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19137768

Source DB:  PubMed          Journal:  J Drugs Dermatol        ISSN: 1545-9616            Impact factor:   2.114


  8 in total

Review 1.  Acne, the Skin Microbiome, and Antibiotic Treatment.

Authors:  Haoxiang Xu; Huiying Li
Journal:  Am J Clin Dermatol       Date:  2019-06       Impact factor: 7.403

2.  A phase 2 study for evaluating doxycycline 50 mg once daily and 100 mg once daily as preemptive treatment for skin toxicity in patients with metastatic colorectal cancer treated with an anti-EGFR and chemotherapy.

Authors:  Patricia Ramírez-Daffós; Encarnación Jiménez-Orozco; Matilde Bolaños; Beatriz González Astorga; Sandra Rubiales; Eduardo Ceballos-Barbancho; José Manuel Rodríguez García; Juan-José Reina
Journal:  Support Care Cancer       Date:  2022-07-01       Impact factor: 3.359

3.  Acne vulgaris, probiotics and the gut-brain-skin axis - back to the future?

Authors:  Whitney P Bowe; Alan C Logan
Journal:  Gut Pathog       Date:  2011-01-31       Impact factor: 4.181

4.  Problems in the reporting of acne clinical trials: a spot check from the 2009 Annual Evidence Update on Acne Vulgaris.

Authors:  John R Ingram; Douglas J C Grindlay; Hywel C Williams
Journal:  Trials       Date:  2010-07-12       Impact factor: 2.279

5.  Clinical implications of lipid peroxidation in acne vulgaris: old wine in new bottles.

Authors:  Whitney P Bowe; Alan C Logan
Journal:  Lipids Health Dis       Date:  2010-12-09       Impact factor: 3.876

Review 6.  A review of diagnosis and treatment of acne in adult female patients.

Authors:  A U Tan; B J Schlosser; A S Paller
Journal:  Int J Womens Dermatol       Date:  2017-12-23

Review 7.  Periodontal therapeutics: Current host-modulation agents and future directions.

Authors:  Lorne M Golub; Hsi-Ming Lee
Journal:  Periodontol 2000       Date:  2020-02       Impact factor: 12.239

Review 8.  Edible Plants and Their Influence on the Gut Microbiome and Acne.

Authors:  Ashley K Clark; Kelly N Haas; Raja K Sivamani
Journal:  Int J Mol Sci       Date:  2017-05-17       Impact factor: 5.923

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.